The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE ... research is needed in order to further elucidate the mechanisms of action of this class of drugs and establish their ...

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

Learn how common medications like nitroglycerin, antidepressants, and hormone therapies can trigger migraine attacks. Discover ways to manage and discuss options with healthcare providers.

Introduction Recent controlled trials have assessed the efficacy of phospodiesterase-5 (PDE-5) inhibitors in secondary Raynaud's phenomenon (RP). However, the conclusions are conflicting, and whether ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

Neither specific phosphodiesterase inhibitors nor cyclic adenosine monophosphate and cyclic guanosine monophosphate inhibit sustained Ca 2+ elevations in pancreatic acinar cells. Serum levels of ...

The Clean Development Mechanism (CDM), defined in Article 12 of the Protocol, allows a country with an emission-reduction or emission-limitation commitment under the Kyoto Protocol (Annex B Party) to ...

PDE2 (phosphodiesterase 2) is upregulated in human heart failure. Cardiac PDE2‐transgenic mice are protected against contractile dysfunction and arrhythmias in heart failure but whether an acute ...

By testing accessible compounds to dissect multi-functional DDRs and suggesting inhibitor mechanisms from initial docking, the GL approach may enable more groups to help accelerate discovery, suggest ...